23rd WCIRDC Abstract Submissions

Starting June 10, 2025 

Dear Participants,

We are delighted to announce the 23rd World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease (WCIRDC), scheduled to be held from December 4-6, 2025. We are excited to invite you to participate in this prestigious event as presenters of abstracts and contributors to scientific discussions.

To be eligible for publication, at least one author of the accepted abstract must be a registered participant of the 23rd WCIRDC and must have presented the abstract in person at the conference.  Authors of all accepted abstracts will receive a 50% reimbursement on the regular general admission registration fee upon in-person attendance and presentation.    This registration includes full access to on-demand content for 90 days. To qualify for the reimbursement, you must attend the meeting in person and present your poster. Reimbursements are offered exclusively to those who meet this requirement. To request your reimbursement after the conference, please email: JC Javellana  jcj@tmioa.com.

Please note: This reimbursement offer does not apply to Medical Student or Fellow/Resident registrations, nor to On-Demand or One-Day Passes, which will remain available at standard rates.

• Abstracts of exceptional quality will be selected for oral presentation during the meeting. The committee may also consider Late Breaking Abstracts for oral presentation in special cases. Only the highest-ranking abstracts submitted by participants who have registered for full access (in-person + on-demand) will be eligible for the Oral Abstract Presentation and the awards.
• Accepted abstracts submitted by registered participants will have the opportunity to present their posters at the Abstract Hall. Furthermore, all accepted abstracts from registered participants will be published in the journal "Metabolism," with Dr. Christos S. Mantzoros serving as the Editor-in-Chief.
• To encourage academic excellence, the top 6 abstracts will receive awards.

Abstract Submission & Topics: Abstracts should focus on clinical or basic science aspects of insulin resistance in fields such as diabetes, obesity, and cardiovascular disease. Investigations of pathophysiology and effects on key metabolic centers, such as the beta cell, adipocyte, gut, and brain, are of particular interest. Studies related to inflammation, endothelial or other vascular dysfunction and multi-hormonal aspects of obesity will also be considered. Clinical topics may encompass insulin resistance in relation to obesity, diabetes, hypertension, dyslipidemia, cardiovascular disease, renal disease, gonadal dysfunction, liver disease (NAFLD), malignancy, and sleep disorders such as obstructive sleep apnea.

Abstract Oral Presentations: Six of the highest-ranking abstracts will be chosen for the Abstract Oral Presentation Session. Authors of winning abstracts will present their research findings in a 10-minute presentation, followed by a 5-minute Q&A session. If selected, authors are required to register for the meeting and prepare a PowerPoint presentation.

Top Abstract Awards: The highest-ranking abstracts will receive awards at different levels: Gold, Silver, Bronze, and honorable mentions. Award recipients will be chosen from the Abstract Oral Winners.

Abstract Poster Presentations: Accepted abstracts may be presented as posters at the conference. Authors or presenters for poster presentations must be registered participants. The presenter must be one of the authors listed on the abstract. Groups or companies with more than one abstract must assign a separate presenter for each poster presentation.

Eligibility for Publication: To be eligible for publication, at least one author of the accepted abstract must be a registered participant of the 23rd WCIRDC and must have presented the abstract in person at the conference.

Encore abstracts are accepted under special circumstances. Make sure to identify your abstract as an encore if it was published or presented in a different conference. Please note that Encore abstracts will not be published under Metabolism and will not be eligible for oral abstract presentations or awards.  In addition, upon acceptance of your encore abstract, at least one of the authors should be registered for the conference and is present on-site to present their posters during the meeting.

Important Information:

1. Submission period for abstracts is from June 10, 2025 to November 3, 2025
2. Deadline for submission is November 3, 2025 at 11:59 PM, Pacific Standard Time. 
3. A maximum of three abstract submissions will be accepted per group, individual submitter, or company. Authors may be listed on multiple abstracts.
4. Abstracts and scientific material presented at the conference must not have been published or presented prior to December 4, 2025.
5. Abstracts must be submitted electronically and should not exceed 250 words. Tables, graphs, figures, or references should not be included.
6. All materials must arrive on or before the abstract deadline noted.
7. Abstracts will be graded by the scientific planning committee, The International Committee for Insulin Resistance.
8. Poster guidelines, including presentation size and layout details, can be found at wcir.org/poster-guidelines.
9. If an author wishes to make changes or withdraw their abstract, they must notify the WCIRDC team no later than November 24, 2025. Requests submitted after this date may not be accommodated.

Special Notice:

All abstracts are undergoing review to ensure originality and to screen for plagiarism and AI-generated material. Of note, the software used to screen and review is able to identify plagiarism based on all international journals. Abstracts that will be identified as such, will not be published and the authors will be barred from future submission.  

For any inquiries or clarifications, please contact us at info@tmioa.com.

We are looking forward to your valuable contributions and the success of the 23rd WCIRDC.